Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer $(BTC.AU)$. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.